Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2

Cancer Research

Volumn 67, Issue 10, 2007, Pages 4949-4955

  Schepelmann, Silke ^a   Ogilvie, Lesley M ^a   Hedley, Douglas ^a   Friedlos, Frank ^a   Martin, Janet ^a   Scanlon, Ian ^a   Chen, Ping ^b   Marais, Richard ^a   Springer, Caroline J ^a,c  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^b NOVARTIS PHARMA AG   (Switzerland)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CARBOXYPEPTIDASE G2; ONCOLYTIC ADENOVIRUS; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG; ZD 2767P;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA CROSS LINKING; DRUG DISTRIBUTION; DRUG MECHANISM; ENZYME PRODRUG THERAPY; ENZYME SYNTHESIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE THERAPY; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CELL LINE, TUMOR; COLONIC NEOPLASMS; FEMALE; GAMMA-GLUTAMYL HYDROLASE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; NITROGEN MUSTARD COMPOUNDS; ONCOLYTIC VIROTHERAPY; PRODRUGS; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34250375517     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0297     Document Type: Article

References (25)

1. Alemany R, Balague C, Curiel DT. Replicative adenoviruses for cancer therapy. Nat Biotechnol 2000;18:723-7.
2. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007;4:101-17.
3. Reid TR, Freeman S, Post L, McCormick F, Sze DY. Effects of Onyx-015 among metastatic colorectal cancer patients that have failed prior treatment with 5-FU/leucovorin. Cancer Gene Ther 2005;12:673-81.
4. Jia H, Kling J. China offers alternative gateway for experimental drugs. Nat Biotechnol 2006;24:117-8.
5. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879-85.
6. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. Cancer Res 2002;62:6070-9.
7. Hecht JR, Bedford R, Abbruzzese JL, et al. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma. Clin Cancer Res 2003;9:555-61.
8. Schepelmann S, Hallenbeck P, Ogilvie LM, et al. Systemic gene-directed enzyme prodrug therapy of hepatocellular carcinoma using a targeted adenovirus armed with carboxypeptidase G2. Cancer Res 2005;65:5003-8.
9. Schepelmann S, Springer CJ. Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 2006; 6:647-70.
10. Marais R, Spooner RA, Light Y, Martin J, Springer CJ. Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res 1996;56:4735-42.
11. Springer CJ, Dowell R, Burke PJ, et al. Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: a new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J Med Chem 1995;38:5051-65.
12. Francis RJ, Sharma SK, Springer C, et al. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 2002;87:600-7.
13. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 1986;46: 5276-81.
14. Karasarides M, Chiloeches A, Hayward R, et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004;23: 6292-8.
15. Olive PL, Banath JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. Radiat Res 1990;122:86-94.
16. Friedlos F, Davies L, Scanlon I, et al. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models. Cancer Res 2002;62:1724-9.
17. Stribbling SM, Martin J, Pedley RB, Boden JA, Sharma SK, Springer CJ. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft. Cancer Chemother Pharmacol 1997;40:277-84.
18. Shay JW, Bacchetti SA. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
19. Bernt KM, Steinwaerder DS, Ni S, Li ZY, Roffler SR, Lieber A. Enzyme-activated prodrug therapy enhances tumor-specific replication of adenovirus vectors. Cancer Res 2002;62:6089-98.
20. Bergelson JM, Krithivas A, Celi L, et al. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J Virol 1998;72:415-19.
21. Puhlmann M, Gnant M, Brown CK, Alexander HR, Bartlett DL. Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy. Hum Gene Ther 1999; 10:649-57.
22. McCart JA, Puhlmann M, Lee J, et al. Complex interactions between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression. Gene Ther 2000;7:1217-23.
23. Nakamura H, Mullen JT, Chandrasekhar S, Pawlik TM, Yoon SS, Tanabe KK. Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil. Cancer Res 2001;61:5447-52.
24. Pawlik TM, Nakamura H, Mullen JT, et al. Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgene. Cancer 2002;95;1171-81.
25. Chen MJ, Green NK, Reynolds GM, et al. Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1-55K-deleted oncolytic adenovirus vector. Gene Ther 2004; 11:1126-36.